Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding Div RTS (OP:RHHVF)

402.89 -15.95 (-3.81%)
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding Div RTS

< Previous 1 2 3 4 5 6 7 Next >
News headline image
No More Free COVID-19 At-Home Tests, Federal Government Says ↗
CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au 
Via Benzinga
News headline image
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate ↗
Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion).  
Via Benzinga
News headline image
China-Based Jemincare Inks Prostate Cancer Drug Pact With Roche's Genentech ↗
 
Via Benzinga
News headline image
Roche's Polivy Combo Regime Under FDA Review For Type Of Blood Cancer ↗
 
Via Benzinga
News headline image
FDA Approves Expanded Use Of Roche's Influenza Treatment ↗
 
Via Benzinga
News headline image
Amgen's Lumakras/Keytruda/Tecentriq Combo Data Flags Safety Concern ↗
 
Via Benzinga
News headline image
Poseida Shares Rally As Roche Takes Next Big Step Into Allogeneic CAR-T Field ↗
 
Via Benzinga
News headline image
Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product ↗
 
Via Benzinga
News headline image
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Roche's Long-Time CEO Passes Baton, Higher Diagnostics, Medicine Sales Lift 1H Sales & Profit ↗
 
Via Benzinga
News headline image
Roche Launches Dual Antigen & Antibody Hepatitis C Diagnostic Test ↗
 
Via Benzinga
News headline image
New Data Reinforce Favorable Safety, Efficacy Of Roche's Hemlibra For Hemophilia A ↗
 
Via Benzinga
News headline image
Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients ↗
 
Via Benzinga
News headline image
Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients ↗
 
Via Benzinga
News headline image
Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer ↗
 
Via Benzinga
News headline image
Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer ↗
Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung... 
Via Benzinga
News headline image
Roche Releases More Evrysdi Data For Very Young Infants With SMA ↗
 
Via Benzinga
News headline image
Roche's CEO Warns Russia-Ukraine War Causing Problems For Multiple Sclerosis Trials ↗
The development of Roche Holdings AG's (OTC: RHHBY) multiple sclerosis candidate fenebrutinib is negatively impacted by Russia's ongoing invasion of Ukraine. 
Via Benzinga
News headline image
COVID-19 Tests Boost Roche's Q1 Sales, Reaffirms FY22 Outlook ↗
 
Via Benzinga
News headline image
EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs ↗
 
Via Benzinga
News headline image
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis ↗
The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was... 
Via Benzinga
News headline image
Read Why Pliant Therapeutics Shares Are Soaring Today ↗
Pliant Therapeutics Inc (NASDAQ: PLRX) says that with just two FDA-approved Idiopathic Pulmonary Fibrosis drugs, it believes that is a high unmet need. 
Via Benzinga
News headline image
Genentech's Ocrevus Shows Benefit In Disability Progression & Cognitive Decline In Multiple Sclerosis ↗
 
Via Benzinga
News headline image
FDA Grants Priority Review To Roche's Actemra For Hospitalized COVID-19 Adults ↗
 
Via Benzinga
News headline image
Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial ↗
Roche Holding AG's (OTC: RHHBY) Phase 3 SKYSCRAPER-02 study in extensive-stage small-cell lung cancer (ES-SCLC)  
Via Benzinga
News headline image
Drug makers, Scientists Working For Long COVID Treatments: Reuters ↗
Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,  
Via Benzinga
News headline image
Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population ↗
 
Via Benzinga
News headline image
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy ↗
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.